Loading...
•
Jun 30, 2021
Pulse Biosciences Q2 2021 Earnings Report
Pulse Biosciences reported financial results for the second quarter of 2021.
Key Takeaways
Pulse Biosciences reported a GAAP net loss of $15.3 million for the second quarter of 2021, compared to a net loss of $11.3 million for the same period in 2020. Cash, cash equivalents and investments totaled $47.4 million as of June 30, 2021, compared to $59.9 million as of March 31, 2021. The company onboarded 34 controlled launch participant clinics across the U.S., Europe and Canada.
CellFX System Controlled Launch Program participants totaled 49 at the end of Q2, with 34 onboarded during the quarter.
Initiated the transition of clinics from the Controlled Launch Program to commercial use.
Achieved Health Canada Approval for the CellFX System and expanded the Controlled Launch into Canada.
Completed $50 million common stock private placement with the Company’s Chairman Robert W. Duggan.
Pulse Biosciences
Pulse Biosciences
Forward Guidance
Pulse Biosciences anticipates ongoing commercial conversions of controlled launch participants and looks forward to a broader commercial launch late in the year.
Positive Outlook
- Anticipated ongoing commercial conversions of controlled launch participants.
- Well positioned to drive growth through increased adoption of CellFX procedures.
- Looking forward to a broader commercial launch late in the year.
- Delivering the benefits of NPS technology to more patients and clinicians.
- Continued progress on clinical initiatives intended to broaden the CellFX System’s applications in aesthetic dermatology and beyond
Challenges Ahead
- Future impact to the Company’s operations and financial results, if any, from COVID-19 cannot be reasonably estimated.
- Known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control.
- Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission.
- The company has a history of net losses.
- There is no guarantee of future regulatory clearances.